syk-20200930


	September 30		December 31
	2020		2019
	(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	7,083	$	4,337
Marketable securities	78		88
Accounts receivable, less allowance of $125 ($88 in 2019)	2,426		2,893
Inventories:
Materials and supplies	751		677
Work in process	174		178
Finished goods	2,534		2,427
Total inventories	$	3,459	$	3,282
Prepaid expenses and other current assets	499		760
Total current assets	$	13,545	$	11,360
Property, plant and equipment:
Land, buildings and improvements	1,443		1,263
Machinery and equipment	3,396		3,451
Total property, plant and equipment	$	4,839	$	4,714
Less accumulated depreciation	2,310		2,147
Property, plant and equipment, net	$	2,529	$	2,567
Goodwill	9,128		9,069
Other intangibles, net	3,917		4,227
Noncurrent deferred income tax assets	1,627		1,575
Other noncurrent assets	1,540		1,369
Total assets	$	32,286	$	30,167

Liabilities and shareholders' equity
Current liabilities
Accounts payable	$	647	$	675
Accrued compensation	680		955
Income taxes	261		171
Dividends payable	216		213
Accrued expenses and other liabilities	1,766		1,527
Current maturities of debt	1,119		859
Total current liabilities	$	4,689	$	4,400
Long-term debt, excluding current maturities	12,008		10,231
Income taxes	999		1,068
Other noncurrent liabilities	1,604		1,661
Total liabilities	$	19,300	$	17,360
Shareholders' equity
Common stock, $0.10 par value	38		37
Additional paid-in capital	1,736		1,628
Retained earnings	12,129		11,748
Accumulated other comprehensive loss	(917)		(606)
Total shareholders' equity	$	12,986	$	12,807
Total liabilities and shareholders' equity	$	32,286	$	30,167


	Nine Months
	2020		2019
Operating activities
Net earnings	$	1,031	$	1,358
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	247		231
Amortization of intangible assets	342		352
Asset impairments	161		2
Share-based compensation	115		95
Recall charges	(4)		179
Sale of inventory stepped-up to fair value at acquisition	9		55
Changes in operating assets and liabilities:
Accounts receivable	467		(124)
Inventories	(154)		(414)
Accounts payable	(26)		37
Accrued expenses and other liabilities	(184)		64
Recall-related payments	(13)		(172)
Income taxes	5		(94)
Other, net	44		(113)
Net cash provided by operating activities	$	2,040	$	1,456
Investing activities
Acquisitions, net of cash acquired	(26)		(281)
Purchases of marketable securities	(34)		(57)
Proceeds from sales of marketable securities	44		52
Purchases of property, plant and equipment	(322)		(450)
Other investing, net	(11)		—
Net cash used in investing activities	$	(349)	$	(736)
Financing activities
Proceeds (payments) on short-term borrowings, net	3		(7)
Proceeds from issuance of long-term debt	2,293		—
Payments on long-term debt	(500)		(1,341)
Dividends paid	(647)		(585)
Repurchases of common stock	—		(307)
Cash paid for taxes from withheld shares	(79)		(130)
Other financing, net	(24)		10
Net cash provided by (used in) financing activities	$	1,046	$	(2,360)
Effect of exchange rate changes on cash and cash equivalents	9		(28)
Change in cash and cash equivalents	$	2,746	$	(1,668)
Cash and cash equivalents at beginning of period	4,337		3,616
Cash and cash equivalents at end of period	$	7,083	$	1,948

NOTE 1 - BASIS OF PRESENTATION

General Information

Management believes the accompanying unaudited Consolidated Financial Statements contain all adjustments, including normal recurring items, considered necessary to fairly present the financial position of Stryker Corporation and its consolidated subsidiaries ("Stryker," the "Company," "we," us" or "our") on September 30, 2020 and the results of operations for the three and nine months 2020. The results of operations included in these Consolidated Financial Statements may not necessarily be indicative of our annual results. These statements should be read in conjunction with our Annual Report on Form 10-K for 2019.

Certain prior year amounts have been reclassified to conform with current year presentation of segment results.

New Accounting Pronouncements Not Yet Adopted

We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.

Accounting Pronouncements Recently Adopted

On January 1, 2020 we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses for accounts receivables, loans and other financial instruments. The adoption of this update did not have a material impact on our Consolidated Financial Statements.

NOTE 2 - REVENUE RECOGNITION

Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2019.

We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.


Net Sales by Product Line
	Three Months				Nine Months
	2020		2019		2020		2019
Orthopaedics:
Knees	$	435	$	426	$	1,108	$	1,305
Hips	334		332		866		1,011
Trauma and Extremities	430		407		1,152		1,197
Other	118		97		307		272
	$	1,317	$	1,262	$	3,433	$	3,785
MedSurg:
Instruments	$	467	$	452	$	1,308	$	1,417
Endoscopy	467		474		1,238		1,424
Medical	600		554		1,819		1,627
Sustainability	66		72		181		212
	$	1,600	$	1,552	$	4,546	$	4,680
Neurotechnology and Spine:
Neurotechnology	$	518	$	490	$	1,370	$	1,443
Spine	302		283		740		845
	$	820	$	773	$	2,110	$	2,288
Total	$	3,737	$	3,587	$	10,089	$	10,753


Net Sales by Geography
	Three Months 2020				Three Months 2019
	United States		International		United States		International
Orthopaedics:
Knees	$	332	$	103	$	318	$	108
Hips	223		111		211		121
Trauma and Extremities	285		145		262		145
Other	97		21		81		16
	$	937	$	380	$	872	$	390
MedSurg:
Instruments	$	369	$	98	$	357	$	95
Endoscopy	380		87		377		97
Medical	455		145		442		112
Sustainability	65		1		71		1
	$	1,269	$	331	$	1,247	$	305
Neurotechnology and Spine:
Neurotechnology	$	323	$	195	$	316	$	174
Spine	219		83		209		74
	$	542	$	278	$	525	$	248
Total	$	2,748	$	989	$	2,644	$	943


Net Sales by Geography
	Nine Months 2020				Nine Months 2019
	United States		International		United States		International
Orthopaedics:
Knees	$	833	$	275	$	962	$	343
Hips	564		302		643		368
Trauma and Extremities	753		399		768		429
Other	262		45		223		49
	$	2,412	$	1,021	$	2,596	$	1,189
MedSurg:
Instruments	$	1,028	$	280	$	1,121	$	296
Endoscopy	997		241		1,136		288
Medical	1,363		456		1,288		339
Sustainability	179		2		210		2
	$	3,567	$	979	$	3,755	$	925
Neurotechnology and Spine:
Neurotechnology	$	835	$	535	$	929	$	514
Spine	543		197		638		207
	$	1,378	$	732	$	1,567	$	721
Total	$	7,357	$	2,732	$	7,918	$	2,835

Contract Assets and Liabilities

On September 30, 2020 there were no contract assets recorded on our Consolidated Balance Sheets.

Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $389 and $313 on September 30, 2020 and December 31, 2019.

NOTE 3 - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI)


Three Months 2020	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	(3)	$	(187)	$	(9)	$	(516)	$	(715)
OCI	—		(11)		2		(248)		(257)
Income taxes	—		3		(1)		59		61
Reclassifications to:
Cost of sales	—		—		(3)		—		(3)
Other (income) expense	—		2		(1)		(7)		(6)
Income taxes	—		—		1		2		3
Net OCI	$	—	$	(6)	$	(2)	$	(194)	$	(202)
Ending	$	(3)	$	(193)	$	(11)	$	(710)	$	(917)


Three Months 2019	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	(3)	$	(148)	$	37	$	(516)	$	(630)
OCI	—		11		(18)		116		109
Income taxes	—		1		10		(32)		(21)
Reclassifications to:
Cost of sales	—		—		(2)		—		(2)
Other (income) expense	—		1		—		(7)		(6)
Income taxes	—		—		(5)		2		(3)
Net OCI	$	—	$	13	$	(15)	$	79	$	77
Ending	$	(3)	$	(135)	$	22	$	(437)	$	(553)


Nine Months 2020	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	(3)	$	(179)	$	47	$	(471)	$	(606)
OCI	—		(25)		(70)		(285)		(380)
Income taxes	—		5		18		61		84
Reclassifications to:
Cost of sales	—		—		(3)		—		(3)
Other (income) expense	—		8		(4)		(20)		(16)
Income taxes	—		(2)		1		5		4
Net OCI	$	—	$	(14)	$	(58)	$	(239)	$	(311)
Ending	$	(3)	$	(193)	$	(11)	$	(710)	$	(917)


Nine Months 2019	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	(4)	$	(137)	$	50	$	(540)	$	(631)
OCI	1		(5)		(34)		144		106
Income taxes	—		4		18		(36)		(14)
Reclassifications to:
Cost of sales	—		—		(4)		—		(4)
Other (income) expense	—		4		—		(7)		(3)
Income taxes	—		(1)		(8)		2		(7)
Net OCI	$	1	$	2	$	(28)	$	103	$	78
Ending	$	(3)	$	(135)	$	22	$	(437)	$	(553)

NOTE 4 - DERIVATIVE INSTRUMENTS

We use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both derivative and non-derivative financial instruments) and interest rate derivative instruments to manage the impact of currency exchange and interest rate fluctuations on earnings, cash flow and equity. We do not enter into derivative instruments for speculative purposes. We are exposed to potential credit loss in the event of nonperformance by our counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum loss exposure is the asset balance of the instrument. We have not changed our hedging

strategies, accounting practices or objectives from those disclosed in our Annual Report on Form 10-K for 2019.

Foreign Currency Hedges


September 2020	Cash Flow		Net Investment		Non-Designated		Total
Gross notional amount	$	824	$	1,169	$	5,619	$	7,612
Maximum term in days							1372
Fair value:
Other current assets	$	10	$	—	$	13	$	23
Other noncurrent assets	1		43		—		44
Other current liabilities	(6)		—		(97)		(103)
Other noncurrent liabilities	(2)		—		—		(2)
Total fair value	$	3	$	43	$	(84)	$	(38)


December 2019	Cash Flow		Net Investment		Non-Designated		Total
Gross notional amount	$	801	$	1,113	$	6,174	$	8,088
Maximum term in days							1646
Fair value:
Other current assets	$	5	$	—	$	180	$	185
Other noncurrent assets	1		40		—		41
Other current liabilities	(10)		—		(11)		(21)
Other noncurrent liabilities	(2)		—		—		(2)
Total fair value	$	(6)	$	40	$	169	$	203

In December 2019 and November 2018 we designated the issuance of €2,400 and €2,250 of senior unsecured notes as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro-denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries. On September 30, 2020 the total after tax gain (loss) amount in AOCI related to these designated net investment hedges was ($179).

In July 2019 we entered into €1.0 billion in certain forward currency contracts and designated these as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros.

Net Currency Exchange Rate Gains (Losses)


		Three Months				Nine Months
Derivative instrument	Recorded in:	2020		2019		2020		2019
Cash Flow	Cost of sales	$	3	$	2	$	3	$	4
Net Investment	Other income (expense), net	7		7		20		7
Non-Designated	Other income (expense), net	(3)		(6)		(12)		(10)
	Total	$	7	$	3	$	11	$	1

Pretax gains (losses) on derivatives designated as cash flow of $6 and net investment hedges of $27 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense) in earnings within 12 months as of September 30, 2020. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge instruments as we elected to exclude the initial value of the component related to the spot-forward difference from the effectiveness assessment.

Interest Rate Hedges

In conjunction with our offerings of senior unsecured notes in December 2019 and June 2020 we terminated cash flow hedges with gross notional amounts of €600 and $500 designated as

forward starting interest rate swaps of our interest rates, the impact of which will be recognized over time within interest expense. Pretax gains recorded in AOCI related to closed interest rate hedges of $6 are expected to be reclassified to other income (expense) in earnings within 12 months of September 30, 2020.

On September 30, 2020 we had interest rate swap agreements with notional amounts of $750 designated as forward starting interest rate swaps in anticipation of future debt issuances. Pretax losses of $66 were recorded in AOCI as of September 30, 2020. Upon the probable issuance of the debt, these amounts will be released to interest expense over the term of the debt. The cash flow effect of these hedges is recorded in cash flow from operations.

NOTE 5 - FAIR VALUE MEASUREMENTS

Our policies for managing risk related to foreign currency, interest rates, credit and markets and our process for determining fair value have not changed from those described in our Annual Report on Form 10-K for 2019.

There were no significant transfers into or out of any level in 2020.


Assets Measured at Fair Value	September		December
	2020		2019
Cash and cash equivalents	$	7,083	$	4,337
Trading marketable securities	154		149
Level 1 - Assets	$	7,237	$	4,486
Available-for-sale marketable securities:
Corporate and asset-backed debt securities	$	37	$	32

United States agency debt securities	6		2
United States Treasury debt securities	34		49
Certificates of deposit	1		5
Total available-for-sale marketable securities	$	78	$	88
Foreign currency exchange forward contracts	67		226
Interest rate swap asset	—		17
Level 2 - Assets	$	145	$	331
Total assets measured at fair value	$	7,382	$	4,817


Liabilities Measured at Fair Value	September		December
	2020		2019
Deferred compensation arrangements	$	154	$	149
Level 1 - Liabilities	$	154	$	149
Foreign currency exchange forward contracts	$	105	$	23
Interest rate swap liability	65		—
Level 2 - Liabilities	$	170	$	23
Contingent consideration:
Beginning	$	306	$	117
Additions	5		298
Change in estimate	6		(10)
Settlements	(30)		(99)
Ending	$	287	$	306
Level 3 - Liabilities	$	287	$	306
Total liabilities measured at fair value	$	611	$	478


Fair Value of Available for Sale Securities by Maturity
	September 2020		December 2019
Due in one year or less	$	40	$	50
Due after one year through three years	$	38	$	38

On September 30, 2020 and December 31, 2019 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest and marketable securities income recorded in other income (expense), net, was $19 and $36 in the three months and $84 and $109 in the nine months 2020 and 2019.

Our investments in available-for-sale marketable securities had a minimum credit quality rating of A2 (Moody's), A (Standard & Poor's) and A (Fitch). We do not plan to sell the investments, and it is not more likely than not that we will be required to sell the

investments before recovery of their amortized cost basis, which may be maturity.

NOTE 6 - CONTINGENCIES AND COMMITMENTS

We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters, the most significant of which are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings, the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for product liability claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.

Recall Matters

In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. In November 2014 we entered into a settlement agreement to compensate eligible United States patients who had revision surgery prior to November 3, 2014 and in December 2016 the settlement program was extended to patients who had revision surgery prior to December 19, 2016. In September 2020 we entered into a second settlement agreement to compensate eligible United States patients who had revision surgery prior to September 9, 2020. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, there are remaining lawsuits that we will continue to defend against.

In August 2016 and May 2018 we voluntarily recalled certain lot-specific sizes and offsets of LFIT Anatomic CoCr V40 Femoral Heads. Product liability lawsuits and claims relating to this voluntary recall have been filed against us. In November 2018 we entered into a settlement agreement to resolve a significant number of claims and lawsuits related to the recalls. The specific terms of the settlement agreement, including the financial terms, are confidential.

We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. Based on the information that has been received, we have estimated the remaining range of probable loss related to these matters globally to be approximately $280 to $515. We have recorded charges to earnings representing the minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and

accruals and could have a material adverse effect on our results of operations and cash flows.


Leases	September			December
	2020			2019
Right-of-use assets	$	401		$	384
Lease liabilities, current	$	100		$	86
Lease liabilities, non-current	$	310		$	301

Other information
Weighted-average remaining lease term	5.5 years			6.2 years
Weighted-average discount rate	2.87		%	3.34		%


	Three Months			Nine Months
	2020		2019	2020	2019
Operating lease cost	$	27	34	94	102

NOTE 7 - ACQUISITIONS

We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. The aggregate purchase price of our acquisitions, net of cash acquired was $26 and $446 in the nine months 2020 and 2019.

In October 2019 we completed the acquisition of Mobius Imaging and Cardan Robotics for net cash consideration of $360 and future regulatory and commercial milestone payments of up to $130. Mobius Imaging is a leader in point-of-care imaging technology focused on integrating advanced imaging technologies into medical workflow. Cardan Robotics is working to develop innovative robotics and navigation technology systems for surgical and interventional radiology procedures. Mobius Imaging and Cardan Robotics (Mobius) are part of our Spine business within Neurotechnology and Spine. For income tax purposes the acquisition was treated as an asset purchase. Goodwill attributable to the acquisition is deductible for tax purposes.

In March 2019 we completed the acquisition of OrthoSpace, Ltd. (OrthoSpace) for net cash consideration of $110 and future regulatory milestone payments of up to $110. OrthoSpace is a medical device company specializing in orthopaedic biodegradable technology for the treatment of irreparable rotator cuff tears. OrthoSpace is part of our Endoscopy business within MedSurg. Goodwill attributable to the acquisition is not deductible for tax purposes.

In November 2019 we announced a definitive agreement to acquire all of the issued and outstanding ordinary shares of Wright Medical Group N.V. (Wright) for $30.75 per share, or an aggregate purchase price of approximately $5.4 billion (including convertible notes). Pursuant to the agreement, on December 13, 2019 our wholly owned subsidiary, Stryker B.V., commenced a tender offer to purchase all of the outstanding ordinary shares, par value €0.03 per share, of Wright at a price of $30.75 per share, without interest, but subject to any applicable withholding of taxes. We expect the acquisition to close in the fourth quarter of 2020, subject to the expiration of the waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the receipt of other required approvals and clearances under applicable antitrust laws and other customary conditions. Wright is a global medical device company focused on extremities and biologics. Following closing, we plan to integrate Wright into our Trauma and Extremities business within Orthopaedics.

Purchase price allocations for our significant acquisitions are:


Purchase Price Allocation of Acquired Net Assets
	2019
	Mobius		OrthoSpace
Tangible assets:
Accounts receivable	$	3	$	1
Inventory	6		1
Other assets	2		1
Contingent consideration	(4)		—
Other liabilities	(10)		(29)
Intangible assets:
Customer relationship	7		—


Developed technology and patents	59		120
In-process research and development	98		—
Non-compete agreements	9		—
Goodwill	303		114
Purchase price, net of cash acquired	$	473	$	208
Weighted-average life of intangible assets	12		18

The purchase price allocation for Mobius is based on preliminary valuations, primarily related to intangible assets that are subject to change within the measurement period. The purchase price allocation for OrthoSpace was finalized in 2020.


Estimated Amortization Expense
Remainder of 2020		2021		2022		2023		2024
$	115	$	446	$	436	$	421	$	390

NOTE 8 - DEBT AND CREDIT FACILITIES

We have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on September 30, 2020.

Our commercial paper program allows us to have a maximum of $1,500 in commercial paper outstanding with maturities up to 397 days from the date of issuance. On September 30, 2020 there were no amounts outstanding under our commercial paper program.


Summary of Total Debt			September 2020		December 2019
Senior unsecured notes:
	Rate	Due
	4.375%	January 15, 2020	$	—	$	500
	Variable	November 30, 2020	351		333
	2.625%	March 15, 2021	750		749
	1.125%	November 30, 2023	640		609
	3.375%	May 15, 2024	590		587
	0.250%	December 3, 2024	987		938
	1.150%	June 15, 2025	644		—
	3.375%	November 1, 2025	747		746
	3.500%	March 15, 2026	992		991
	2.125%	November 30, 2027	871		829
	3.650%	March 7, 2028	596		596
	0.750%	March 1, 2029	929		884
	1.950%	June 15, 2030	988		—
	2.625%	November 30, 2030	749		712
	1.000%	December 3, 2031	865		823
	4.100%	April 1, 2043	392		391
	4.375%	May 15, 2044	395		395
	4.625%	March 15, 2046	981		981
	2.900%	June 15, 2050	641		—

Other			19		26
Total debt			$	13,127	$	11,090
Less current maturities of debt			1,119		859
Total long-term debt			$	12,008	$	10,231


	September 2020		December 2019
Unamortized debt issuance costs	$	71	$	58
Available secured borrowing capacity	$	2,904	$	1,403
Fair value of senior unsecured notes	$	14,366	$	11,910

The fair value of the senior unsecured notes was estimated using quoted interest rates, maturities and amounts of borrowings based on quoted active market prices and yields that took into account the underlying terms of the debt instruments. Substantially all of our debt is classified within Level 2 of the fair value hierarchy.

In January 2020 we repaid $500 of senior unsecured notes with a coupon of 4.375% that were due on January 15, 2020.

On April 30, 2020 we amended our primary credit facility. The principal change was to increase the leverage ratio financial covenant from 3.5:1 to 4.5:1 at the end of each fiscal quarter ending on or prior to June 30, 2021.

On April 30, 2020 we entered into a credit agreement that provides for up to $1,500 of borrowings in United States Dollars pursuant to a 364-day revolving credit facility, which matures on April 29, 2021 and is available for working capital and general corporate purposes.

In June 2020 we issued $650 of senior unsecured notes with a fixed interest rate of 1.150% due on June 15, 2025, $1,000 of senior unsecured notes with a fixed interest rate of 1.950% due on June 15, 2030 and $650 of senior unsecured notes with a fixed interest rate of 2.900% due on June 15, 2050. The 2025 and 2030 notes are subject to a special mandatory redemption feature in which we will be required to redeem the notes in whole at a price equal to 101% of the aggregate principal amount plus accrued and unpaid interest if we do not consummate the Wright tender offer on or before February 4, 2021.

NOTE 9 - INCOME TAXES

Our effective tax rates were 20.4% and 19.8% in the three months and 19.6% and 16.5% in the nine months 2020 and 2019. The changes in the effective tax rates were primarily due to a change in geographic profit mix in the three months and a favorable audit settlement recorded in 2019 in the nine months.

In March 2020 the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law in the United States. We do not expect the provisions of the CARES Act to have a material impact on our annual effective tax rate or Consolidated Financial Statements in 2020.

NOTE 10 - SEGMENT INFORMATION


	Three Months				Nine Months
	2020		2019		2020		2019
Orthopaedics	$	1,317	$	1,262	$	3,433	$	3,785
MedSurg	1,600		1,552		4,546		4,680
Neurotechnology and Spine	820		773		2,110		2,288
Net sales	$	3,737	$	3,587	$	10,089	$	10,753
Orthopaedics	$	472	$	437	$	1,027	$	1,322
MedSurg	451		394		1,085		1,179
Neurotechnology and Spine	228		199		513		608
Segment operating income	$	1,151	$	1,030	$	2,625	$	3,109
Items not allocated to segments:
Corporate and other	(104)		(117)		(371)		(371)
Acquisition and integration-related charges	(29)		(32)		(85)		(223)
Amortization of intangible assets	(114)		(116)		(342)		(352)
Restructuring-related and other charges	(29)		(48)		(292)		(146)
Medical device regulations	(14)		(15)		(60)		(34)
Recall-related matters	(2)		(49)		4		(179)
Regulatory and legal matters	—		(25)		(5)		(35)
Consolidated operating income	$	859	$	628	$	1,474	$	1,769

There were no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for 2019.

NOTE 11 - ASSET IMPAIRMENTS

The significant negative impact the COVID-19 pandemic has had on Stryker’s operations and financial results has led to the decision to suspend certain in-process investments resulting in charges of $189 to impair certain long-lived assets (primarily the portion of our investment in a new global ERP system that was in-process of being developed for future deployment) and product line and other exit costs in the second quarter of 2020. These charges were included in cost of sales and selling, general and administrative expenses.

ABOUT STRYKER

Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.

We segregate our operations into three reportable business segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. Orthopaedics products consist primarily of implants used in hip and knee joint replacements and trauma and extremities surgeries. MedSurg products include surgical equipment and surgical navigation systems (Instruments), endoscopic and communications systems (Endoscopy), patient handling, emergency medical equipment and intensive care disposable products (Medical), reprocessed and remanufactured medical devices (Sustainability) and other medical device products used in a variety of medical specialties. Neurotechnology and Spine products include neurosurgical, neurovascular and spinal implant devices.

COVID-19 Pandemic

The COVID-19 global pandemic has led to severe disruptions in the market and the global and United States economies that may continue for a prolonged duration and trigger a recession or a period of economic slowdown. In response, various governmental authorities and private enterprises have implemented numerous measures to contain the pandemic, such as travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns. A significant number of our global suppliers, vendors, distributors and manufacturing facilities are located in regions that have been affected by the pandemic. Those operations have been materially adversely affected by restrictive government and private enterprise measures implemented in response to the pandemic.

Some of our products are particularly sensitive to reductions in deferrable medical procedures. Deferrable medical procedures were suspended in the first quarter of 2020 in many of the markets where our products are marketed and sold, which negatively affected our business, cash flows, financial condition and results of operations. While we have seen progressive improvement in the second and third quarters, to the extent individuals are required to continue to de-prioritize or delay deferrable procedures as a result of the COVID-19 pandemic or otherwise, our business, cash flows, financial condition and results of operations could be negatively affected.

Overview of the Three and Nine Months

The response to the COVID-19 pandemic has included unprecedented measures to slow the spread of the virus taken by

local governments and health care authorities globally, including the postponement of deferrable medical procedures and social contact restrictions, which have had, and we expect will continue to have, a significant negative impact on Stryker’s operations and financial results. While we are still recovering from the impacts of the COVID-19 pandemic, most of our businesses reported overall increased unit volume during the third quarter.

In the three months 2020 we achieved sales growth of 4.2%. Excluding the impact of acquisitions sales grew 3.3% in constant currency. We reported operating income margin of 23.0%, net earnings of $621 and net earnings per diluted share of $1.63. Excluding the impact of certain items, we expanded adjusted operating income margin(1) by 260 bps to 28.0%, with adjusted net earnings(1) of $812 and growth of 12.0% in adjusted net earnings per diluted share(1).

In the nine months 2020 we experienced sales declines of 6.2%. Excluding the impact of acquisitions sales decreased 6.3% in constant currency. We reported operating income margin of 14.6%, net earnings of $1,031 and net earnings per diluted share of $2.71, including $170 of charges related to certain in-process asset impairments (primarily the portion of our investment in a new global ERP system that was in-process of being developed for future deployment) and product line and other exit costs resulting from our decision to suspend certain investments due to pandemic-related constraints. Excluding the impact of certain items, adjusted operating income margin(1) was 22.3%, with adjusted net earnings(1) of $1,756 and a reduction of 19.9% in adjusted net earnings per diluted share(1).

Recent Developments

In January 2020 we repaid $500 of our senior unsecured notes with a coupon of 4.375% that were due on January 15, 2020. In June 2020 we issued $650 of senior unsecured notes with a fixed interest rate of 1.150% due on June 15, 2025, $1,000 of senior unsecured notes with a fixed interest rate of 1.950% due on June 15, 2030 and $650 of senior unsecured notes with a fixed interest rate of 2.900% due on June 15, 2050. Refer to Note 8 to our Consolidated Financial Statements for further Information.

In the nine months 2020 we did not repurchase any shares of our common stock under our authorized repurchase program. The total dollar value of shares of our common stock that could be acquired under our authorized repurchase program was $1,033 as of September 30, 2020. As previously announced we intend to maintain the suspension of our share repurchase program through 2021.


Supplemental Net Sales Growth Information
	Three Months														Nine Months
					Percentage Change														Percentage Change
									United States		International												United States		International
	2020		2019		As Reported		Constant Currency		As Reported		As Reported		Constant Currency		2020		2019		As Reported		Constant Currency		As Reported		As Reported		Constant Currency
Orthopaedics:
Knees	$	435	$	426	2.2	%	1.7	%	4.6	%	(4.8)	%	(6.9)	%	$	1,108	$	1,305	(15.1)	%	(14.8)	%	(13.4)	%	(19.8)	%	(18.8)	%
Hips	334		332		0.4		(0.1)		5.3		(8.2)		(9.7)		866		1,011		(14.4)		(13.9)		(12.3)		(18.1)		(16.8)
Trauma and Extremities	430		407		5.6		4.7		9.0		(0.5)		(3.0)		1,152		1,197		(3.8)		(3.5)		(1.9)		(7.1)		(6.4)
Other	118		97		22.5		22.2		20.0		34.9		33.0		307		272		13.0		13.1		17.5		(7.5)		(6.7)
	$	1,317	$	1,262	4.4	%	3.8	%	7.5	%	(2.6)	%	(4.7)	%	$	3,433	$	3,785	(9.3)	%	(9.0)	%	(7.1)	%	(14.2)	%	(13.2)	%
MedSurg:
Instruments	$	467	$	452	3.4	%	3.1	%	3.1	%	4.7	%	2.9	%	$	1,308	$	1,417	(7.7)	%	(7.4)	%	(8.4)	%	(5.1)	%	(3.5)	%
Endoscopy	467		474		(1.3)		(1.5)		1.0		(10.1)		(11.0)		1,238		1,424		(13.0)		(12.7)		(12.2)		(16.4)		(14.8)
Medical	600		554		8.3		8.0		3.0		29.0		27.8		1,819		1,627		11.8		12.6		5.8		34.6		38.8
Sustainability	66		72		(8.7)		(8.7)		(8.9)		nm		nm		181		212		(14.7)		(14.7)		(14.7)		nm		nm
	$	1,600	$	1,552	3.2	%	2.9	%	1.7	%	8.9	%	7.6	%	$	4,546	$	4,680	(2.9)	%	(2.4)	%	(5.0)	%	5.9	%	8.4	%
Neurotechnology and Spine:
Neurotechnology	$	518	$	490	5.7	%	5.1	%	1.9	%	12.6	%	11.1	%	$	1,370	$	1,443	(5.1)	%	(4.7)	%	(10.2)	%	4.2	%	5.3	%
Spine	302		283		6.6		6.1		4.9		11.3		9.6		740		845		(12.4)		(12.1)		(14.8)		(4.9)		(3.9)
	$	820	$	773	6.0	%	5.5	%	3.1	%	12.2	%	10.6	%	$	2,110	$	2,288	(7.8)	%	(7.4)	%	(12.1)	%	1.6	%	2.6	%
Total	$	3,737	$	3,587	4.2	%	3.8	%	3.9	%	5.0	%	3.3	%	$	10,089	$	10,753	(6.2)	%	(5.8)	%	(7.1)	%	(3.6)	%	(2.1)	%

Orthopaedics Net Sales

Orthopaedics net sales increased 4.4% in the three months 2020 as reported and 3.8% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.6%. Net sales in constant currency increased 5.9% from increased unit volume partially offset by 2.1% from lower prices. The unit volume increase was primarily due to higher shipments of knee, hip and trauma and extremities products.

Orthopaedics net sales decreased 9.3% in the nine months 2020 as reported and 9.0% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.3%. Net sales in constant currency decreased due to the postponement of deferrable medical procedures as part of the global response to the COVID-19 pandemic with 7.4% from lower unit volume and 1.6% from lower prices. The unit volume decrease was primarily due to lower shipments of knee and hip products.

MedSurg Net Sales

MedSurg net sales increased 3.2% in the three months 2020 as reported and 2.9% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.3%. Excluding the 0.4% impact of acquisitions, net sales in constant currency increased by 3.1% from increased unit volume partially offset by 0.6% due to lower prices. The unit volume increase was primarily due to higher shipments of instruments and medical products partially offset by lower shipments of sustainability solutions products.

MedSurg net sales decreased 2.9% in the nine months 2020 as reported and 2.4% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.5%. Excluding the 0.5% impact of acquisitions, net sales in constant currency decreased by 2.9% from lower unit volume. The unit volume decrease was primarily due to lower shipments of instruments, endoscopy and sustainability solutions products partially offset by higher shipments of medical products.

Neurotechnology and Spine Net Sales

Neurotechnology and Spine net sales increased 6.0% in the three months 2020 as reported and 5.5% in constant currency, as foreign currency exchange rates positively impacted net sales by 0.5%. Excluding the 1.2% impact of acquisitions, net sales in constant currency increased by 6.0% from increased unit volume partially offset by 1.7% due to lower prices. The unit volume increase was due to higher shipments of neurotechnology and spine products.

Neurotechnology and Spine net sales decreased 7.8% in the nine months 2020 as reported and 7.4% in constant currency, as foreign currency exchange rates negatively impacted net sales by 0.4%. Excluding the 1.2% impact of acquisitions, net sales in constant currency decreased by 8.2% from decreased unit volume and 0.4% due to lower prices. The unit volume decrease was due to lower shipments of neurotechnology and spine products.

Gross Profit

Gross profit as a percentage of sales in the three months 2020 increased to 65.9% from 65.0% in 2019. Excluding the impact of the items noted below, gross profit increased to 65.9% of sales in the three months 2020 from 65.7% in 2019 primarily due to leverage from higher sales volumes partially offset by lower selling prices.

Gross profit was significantly negatively impacted by the global response to the COVID-19 pandemic in the nine months 2020, decreasing as a percentage of sales to 62.8% from 65.0% in 2019. Excluding the impact of the items noted below, gross profit

decreased to 63.3% of sales in the nine months 2020 from 65.7% in 2019 primarily due to lower sales volumes, lower selling prices, lower manufacturing volumes and unfavorable product mix due to the postponement of deferrable medical procedures as part of the global response to the COVID-19 pandemic.


					Percent Net Sales
Three Months	2020		2019		2020		2019
Reported	$	2,461	$	2,330	65.9	%	65.0	%
Inventory stepped-up to fair value	—		17		—		0.4


Restructuring-related and other charges	—		10		—		0.3
Medical device regulations	—		—		—		—



Adjusted	$	2,461	$	2,357	65.9	%	65.7	%


					Percent Net Sales
Nine Months	2020		2019		2020		2019
Reported	$	6,340	$	6,993	62.8	%	65.0	%
Inventory stepped-up to fair value	9		55		0.1		0.5


Restructuring-related and other charges	36		21		0.4		0.2
Medical device regulations	1		1		—		—



Adjusted	$	6,386	$	7,070	63.3	%	65.7	%

Research, Development and Engineering Expenses

Research, development and engineering expenses decreased $4 or 1.6% in the three months 2020 and decreased as a percentage of sales to 6.5% from 6.9% in 2019. Excluding the impact of the items noted below, expenses decreased to 6.1% of sales in 2020 from 6.5% in 2019. Overall spending levels decreased due to continued operating expense savings actions in response to the COVID-19 pandemic.

Research, development and engineering expenses increased $12 or 1.7% to 7.2% of sales in the nine months 2020 from 6.7% in 2019. Excluding the impact of the items noted below, expenses increased to 6.6% of sales in 2020 from 6.4% in 2019. Projects to develop new products, investments in new technologies, integration of recent acquisitions and the impact of lower sales contributed to the increase partially offset by operating expense savings actions in response to the COVID-19 pandemic that will continue to drive lower spending in the remainder of the year.


					Percent Net Sales
Three Months	2020		2019		2020		2019
Reported	$	242	$	246	6.5	%	6.9	%




Medical device regulations	(13)		(15)		(0.4)		(0.4)



Adjusted	$	229	$	231	6.1	%	6.5	%


					Percent Net Sales
Nine Months	2020		2019		2020		2019
Reported	$	729	$	717	7.2	%	6.7	%




Medical device regulations	(59)		(33)		(0.6)		(0.3)



Adjusted	$	670	$	684	6.6	%	6.4	%

Selling, General and Administrative Expenses

Selling, general and administrative expenses decreased $47 or 3.6% in the three months 2020 and decreased as a percentage of sales to 33.3% from 36.0% in 2019. Excluding the impact of the items noted below, expenses decreased to 31.7% of sales in 2020 from 33.8% in 2019, primarily due to operating expense savings actions taken in response to the COVID-19 pandemic partially offset by the impact of higher sales volumes.

Selling, general and administrative expenses decreased $177 or 4.5% in the nine months 2020 and increased as a percentage of sales to 37.7% from 37.0% in 2019 and included charges related to certain in-process asset impairments (primarily the portion of our investment in a new global ERP system that was in-process of being developed for future deployment) and other exit costs resulting from our decision to suspend certain investments due to pandemic-related constraints. Excluding the impact of the items

noted below, expenses increased to 34.3% of sales in 2020 from 33.9% in 2019, primarily due to the impact of lower sales volumes partially offset by operating expense savings actions taken in response to the COVID-19 pandemic that will continue to drive lower spending in the remainder of the year.


					Percent Net Sales
Three Months	2020		2019		2020		2019
Reported	$	1,244	$	1,291	33.3	%	36.0	%

Other acquisition and integration-related	(29)		(15)		(0.8)		(0.4)

Restructuring-related and other charges	(29)		(37)		(0.8)		(1.1)


Regulatory and legal matters	—		(25)		—		(0.7)

Adjusted	$	1,186	$	1,214	31.7	%	33.8	%


					Percent Net Sales
Nine Months	2020		2019		2020		2019
Reported	$	3,799	$	3,976	37.7	%	37.0	%

Other acquisition and integration-related	(76)		(168)		(0.8)		(1.6)

Restructuring-related and other charges	(256)		(125)		(2.6)		(1.2)


Regulatory and legal matters	(5)		(35)		—		(0.3)

Adjusted	$	3,462	$	3,648	34.3	%	33.9	%

Recall Charges

Recall charges were minimal in the three and nine months 2020 and were $49 and $179 in the three and nine months 2019. Charges were primarily due to the previously disclosed Rejuvenate and ABGII Modular-Neck hip stems and LFIT V40 femoral head voluntary recalls. Refer to Note 6 to our Consolidated Financial Statements for further information.

Amortization of Intangible Assets

Amortization of intangible assets was $114 and $116 in the three months and $342 and $352 in the nine months 2020 and 2019. The decrease in 2020 was primarily due to decreased acquisition activity in 2020. Refer to Note 7 to our Consolidated Financial Statements for further information.

Operating Income

Operating income increased $231 or 36.8% to 23.0% of sales in the three months 2020 from 17.5% of sales in 2019. Excluding the impact of the items noted below, operating income increased to 28.0% of sales in 2020 from 25.4% in 2019 primarily due to leverage from higher sales volumes and continued focus on our operating expense savings actions partially offset by lower selling prices.

Operating income was significantly negatively impacted by the global response to the COVID-19 pandemic in the nine months 2020. Operating income decreased $295 or 16.7% to 14.6% of sales in the nine months 2020 from 16.5% in 2019. Excluding the impact of the items noted below, operating income decreased to 22.3% of sales in 2020 from 25.5% in 2019 primarily due to unfavorable business mix and the impact of lower sales volumes from the postponement of deferrable medical procedures as part of the global response to the COVID-19 pandemic partially offset by continued focus on our operating expense savings actions that will continue to drive lower spending in the remainder of the year.


					Percent Net Sales
Three Months	2020		2019		2020		2019
Reported	$	859	$	628	23.0	%	17.5	%
Inventory stepped-up to fair value	—		17		—		0.5
Other acquisition and integration-related	29		15		0.7		0.4
Amortization of purchased intangible assets	114		116		3.1		3.2
Restructuring-related and other charges	29		48		0.7		1.3
Medical device regulations	14		15		0.4		0.4
Recall-related matters	2		49		0.1		1.4
Regulatory and legal matters	—		25		—		0.7

Adjusted	$	1,047	$	913	28.0	%	25.4	%


					Percent Net Sales
Nine Months	2020		2019		2020		2019
Reported	$	1,474	$	1,769	14.6	%	16.5	%
Inventory stepped-up to fair value	9		55		0.1		0.5
Other acquisition and integration-related	76		168		0.8		1.6
Amortization of purchased intangible assets	342		352		3.3		3.2
Restructuring-related and other charges	292		146		2.9		1.4
Medical device regulations	60		34		0.6		0.3
Recall-related matters	(4)		179		—		1.7
Regulatory and legal matters	5		35		—		0.3

Adjusted	$	2,254	$	2,738	22.3	%	25.5	%

Other Income (Expense), Net

Other income (expense), net was ($79) and ($47) in the three months and ($191) and ($143) in the nine months 2020 and 2019. The increase in net expense in 2020 was primarily due to increased interest expense driven by the additional debt from the bond offerings completed in December 2019 and June 2020.

Income Taxes

Net Earnings

Net earnings increased to $621 or $1.63 per diluted share in the three months 2020 from net earnings of $466 or $1.23 per diluted share in 2019. Adjusted net earnings per diluted share(1) increased 12.0% to $2.14 in 2020 from $1.91 in 2019. The impact of foreign currency exchange rates increased net earnings per diluted share by approximately $0.01 in 2020 and reduced net earnings per diluted share by approximately $0.02 in 2019.

Earnings were significantly negatively impacted by the global response to the COVID-19 pandemic in the nine months 2020. Net earnings decreased to $1,031 or $2.71 per diluted share in the nine months 2020 from $1,358 or $3.58 per diluted share in 2019. Adjusted net earnings per diluted share(1) decreased 19.9% to $4.62 in 2020 from $5.77 in 2019. The impact of foreign currency exchange rates reduced net earnings per diluted share by approximately $0.01 in 2020 and $0.12 in 2019.


					Percent Net Sales
Three Months	2020		2019		2020		2019
Reported	$	621	$	466	16.6	%	13.0	%
Inventory stepped-up to fair value	—		13		—		0.4
Other acquisition and integration-related	24		8		0.6		0.2
Amortization of purchased intangible assets	93		105		2.5		2.8
Restructuring-related and other charges	26		40		0.7		1.1
Medical device regulations	11		13		0.3		0.4
Recall-related matters	2		28		0.1		0.8
Regulatory and legal matters	—		14		—		0.4
Tax matters	35		38		0.9		1.1
Adjusted	$	812	$	725	21.7	%	20.2	%


					Percent Net Sales
Nine Months	2020		2019		2020		2019
Reported	$	1,031	$	1,358	10.2	%	12.6	%
Inventory stepped-up to fair value	6		42		0.1		0.4
Other acquisition and integration-related	60		126		0.6		1.2
Amortization of purchased intangible assets	277		294		2.6		2.8
Restructuring-related and other charges	238		122		2.4		1.1
Medical device regulations	47		28		0.5		0.3
Recall-related matters	(2)		144		—		1.3
Regulatory and legal matters	6		19		0.1		0.2
Tax matters	93		58		0.9		0.5
Adjusted	$	1,756	$	2,191	17.4	%	20.4	%

Non-GAAP Financial Measures

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted research, development and engineering expenses; adjusted operating income; adjusted other income (expense), net; adjusted effective income tax rate; adjusted net earnings; and adjusted net earnings per diluted share (Diluted EPS). We believe these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures. To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates and acquisitions, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year results at prior year average foreign currency exchange rates excluding the impact of acquisitions. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of

earnings. These adjustments are irregular in timing and may not be indicative of our past and future performance. The following are examples of the types of adjustments that may be included in a period:

1.Acquisition and integration-related costs. Costs related to integrating recently acquired businesses and specific costs (e.g., inventory step-up and deal costs) related to the consummation of the acquisition process.

2.Amortization of purchased intangible assets. Periodic amortization expense related to purchased intangible assets.

3.Restructuring-related and other charges. Costs associated with the termination of sales relationships in certain countries, workforce reductions, elimination of product lines, certain long-lived asset impairments and associated costs and other restructuring-related activities.

4.Medical Device Regulations. Costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the European Union and China regulations for medical devices.

5.Recall-related matters. Our best estimate of the minimum of the range of probable loss to resolve the Rejuvenate, LFIT V40 and other product recalls.

6.Regulatory and legal matters. Our best estimate of the minimum of the range of probable loss to resolve certain regulatory matters and other legal settlements.

7.Tax matters. Charges represent the impact of accounting for certain significant and discrete tax items.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, research, development and engineering expenses, operating income, other income (expense), net, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures at the end of the discussion of Consolidated Results of Operations below. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The weighted-average diluted shares outstanding used in the calculation of non-GAAP net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period.

FINANCIAL CONDITION AND LIQUIDITY


Nine Months	2020		2019
Net cash provided by operating activities	$	2,040	$	1,456
Net cash used in investing activities	(349)		(736)
Net cash provided by (used in) financing activities	1,046		(2,360)
Effect of exchange rate changes on cash and cash equivalents	9		(28)
Change in cash and cash equivalents	$	2,746	$	(1,668)

Operating Activities

Cash provided by operating activities was $2,040 and $1,456 in the nine months 2020 and 2019. The increase was primarily due to higher accounts receivable collections and less spending on inventory due to lower production from lower sales partially offset by decreased net earnings.

Investing Activities

Cash used in investing activities was $349 and $736 in the nine months 2020 and 2019. The decrease in cash used was primarily due to decreased payments for acquisitions in 2020.

Financing Activities

Cash provided by (used in) financing activities was $1,046 and $2,360 in the nine months 2020 and 2019. The change in cash was primarily driven by the issuance of $2,300 of notes in June 2020, partially offset by the repayment of $500 of notes upon maturity in January 2020 compared to repayments of $1,341 of debt in the nine months 2019, along with the suspension of share repurchases.


Nine Months	2020		2019
Total dividends paid to common shareholders	$	647	$	585
Total amount paid to repurchase common stock	$	—	$	307
Shares of repurchased common stock (in millions)	—		1.9

Liquidity

Cash, cash equivalents and marketable securities were $7,161 and $4,425 on September 30, 2020 and December 31, 2019. Current assets exceeded current liabilities by $8,856 and $6,960 on September 30, 2020 and December 31, 2019. Despite the impact from the COVID-19 pandemic, we anticipate being able to support our short-term liquidity and operating needs from a variety of sources including cash from operations, commercial paper, existing credit lines and capital expenditure and operating expense reductions. We maintain a revolving credit facility with $1.5 billion of committed capital which expires in August 2023 and a $1.5 billion unsecured revolving credit facility that matures in April 2021.

We raised funds in the capital markets in 2020, 2019 and 2018 and may continue to do so from time-to-time. We continue to have strong investment-grade short-term and long-term debt ratings that we believe should enable us to refinance our debt as needed.

Our cash, cash equivalents and marketable securities held in locations outside the United States was approximately 14% on September 30, 2020 compared to 25% on December 31, 2019.

Critical Accounting Policies

There were no changes to our critical accounting policies from those disclosed in our Annual Report on Form 10-K for 2019.

New Accounting Pronouncements Not Yet Adopted

Refer to Note 1 to our Consolidated Financial Statements for information.

Guarantees and Other Off-Balance Sheet Arrangements

We do not have guarantees or other off-balance sheet financing arrangements, including variable interest entities, of a magnitude that we believe could have a material impact on our financial condition or liquidity.

OTHER MATTERS

Legal and Regulatory Matters

We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of our business, including proceedings related to product, labor, intellectual property and other matters. Refer to Note 6 to our Consolidated Financial Statements for further information.

FORWARD-LOOKING STATEMENTS

This report contains statements referring to us that are not historical facts and are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which are intended to take advantage of the "safe harbor" provisions of the Reform Act, are based on current projections about operations, industry conditions, financial condition and liquidity. Words that identify forward-looking statements include words such as "may," "could," "will," "should," "possible," "plan," "predict," "forecast," "potential," "anticipate," "estimate," "expect," "project," "intend," "believe," "may impact," "on track," "goal," "strategy" and words and terms of similar substance used in connection with any discussion of future operating or financial performance, an acquisition or our businesses. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Those statements are not guarantees and are subject to risks, uncertainties and assumptions that are difficult to predict, including uncertainties related to the impact of the COVID-19 pandemic on our operations and financial results. Therefore, actual results could differ materially and adversely from these forward-looking statements. Some important factors that could cause our actual results to differ from our expectations in any forward-looking statements include those risks discussed in Item 1A. "Risk Factors" of our Annual Report on Form 10-K for 2019 and in Part II, Item 1A. "Risk Factors" on Form 10-Q for the quarter ended March 31, 2020. This Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes to our Consolidated Financial Statements in our Annual Report on Form 10-K for 2019. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.


ITEM 3.			QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We consider our greatest potential areas of market risk exposure to be exchange rate risk and the impacts of the COVID-19 pandemic on our operations and financial results. Quantitative and qualitative disclosures about exchange rate risk are included in Item 7A "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for 2019. There were no material changes from the information provided therein. We are not able to quantify the impacts of the COVID-19 pandemic on our financial results. Qualitative disclosures about the COVID-19 pandemic are included in Part I, Item 2 "Management's Discussion and Analysis of Financial Condition

and Results of Operations" and Part II, Item 1A "Risk Factors" of this Form 10-Q.


ITEM 4.			CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of the Chief Executive Officer and Chief Financial Officer (the Certifying Officers), evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) on September 30, 2020. Based on that evaluation, the Certifying Officers concluded the Company's disclosure controls and procedures were effective as of September 30, 2020.

Changes in Internal Control Over Financial Reporting

There was no change to our internal control over financial reporting during the three months 2020 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION


ITEM 1A.			RISK FACTORS

We are not aware of any material changes to the risk factors included in Item 1A. "Risk Factors" in our Annual Report on Form 10-K for 2019 and Part II, Item 1A. "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.


ITEM 2.			UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

In the three months 2020 we did not issue shares of our common stock as performance incentive awards to employees. When issued, these shares are not registered under the Securities Act of 1933 based on the conclusion that the awards would not be events of sale within the meaning of Section 2(a)(3) of the Act.

In March 2015 we announced that our Board of Directors had authorized us to purchase up to $2,000 of our common stock. The manner, timing and amount of repurchases are determined by management based on an evaluation of market conditions, stock price, and other factors and are subject to regulatory considerations. Purchases are made from time to time in the open market, in privately negotiated transactions or otherwise.


ITEM 6.			EXHIBITS


31(i)*			Certification of Principal Executive Officer of Stryker Corporation pursuant to Rule 13a-14(a).
31(ii)*			Certification of Principal Financial Officer of Stryker Corporation pursuant to Rule 13a-14(a).
32(i)*			Certification by Principal Executive Officer of Stryker Corporation pursuant to 18 U.S.C. Section 1350.
32(ii)*			Certification by Principal Financial Officer of Stryker Corporation pursuant to 18 U.S.C. Section 1350.
101.INS			iXBRL Instance Document
101.SCH			iXBRL Schema Document
101.CAL			iXBRL Calculation Linkbase Document
101.DEF			iXBRL Definition Linkbase Document
101.LAB			iXBRL Label Linkbase Document
101.PRE			iXBRL Presentation Linkbase Document
104			Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
			† Filed with this Form 10-Q
			* Furnished with this Form 10-Q


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $.10 Par Value	SYK	New York Stock Exchange
1.125% Notes due 2023	SYK23	New York Stock Exchange
0.250% Notes due 2024	SYK24A	New York Stock Exchange
2.125% Notes due 2027	SYK27	New York Stock Exchange
0.750% Notes due 2029	SYK29	New York Stock Exchange
2.625% Notes due 2030	SYK30	New York Stock Exchange
1.000% Notes due 2031	SYK31	New York Stock Exchange
Floating Rate Notes due 2020	SYK20A	New York Stock Exchange


		STRYKER CORPORATION
		(Registrant)


Date:	October 30, 2020	/s/ KEVIN A. LOBO
		Kevin A. Lobo
		Chairman and Chief Executive Officer


Date:	October 30, 2020	/s/ GLENN S. BOEHNLEIN
		Glenn S. Boehnlein
		Vice President, Chief Financial Officer


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


Dollar amounts are in millions except per share amounts or as otherwise specified.			1


ITEM 2.			MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


Geographic and Segment Net Sales	Three Months								Nine Months
					Percentage Change								Percentage Change
	2020		2019		As Reported		Constant Currency		2020		2019		As Reported		Constant Currency
Geographic:
United States	$	2,748	$	2,644	3.9	%	3.9	%	$	7,357	$	7,918	(7.1)	%	(7.1)	%
International	989		943		5.0		3.3		2,732		2,835		(3.6)		(2.1)
Total	$	3,737	$	3,587	4.2	%	3.8	%	$	10,089	$	10,753	(6.2)	%	(5.8)	%
Segment:
Orthopaedics	$	1,317	$	1,262	4.4	%	3.8	%	$	3,433	$	3,785	(9.3)	%	(9.0)	%
MedSurg	1,600		1,552		3.2		2.9		4,546		4,680		(2.9)		(2.4)
Neurotechnology and Spine	820		773		6.0		5.5		2,110		2,288		(7.8)		(7.4)
Total	$	3,737	$	3,587	4.2	%	3.8	%	$	10,089	$	10,753	(6.2)	%	(5.8)	%


Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures
Three Months 2020	Gross Profit			Selling, General & Administrative Expenses			Research, Development & Engineering Expenses			Operating Income			Other income (expense), net			Net Earnings			Effective Tax Rate		Diluted EPS
Reported	$	2,461		$	1,244		$	242		$	859		$	(79)		$	621		20.4	%	$	1.63
Reported percent net sales	65.9		%	33.3		%	6.5		%	23.0		%	(2.1)		%	16.6		%
Acquisition and integration-related charges:
Inventory stepped-up to fair value	—			—			—			—			—			—			—		—
Other acquisition and integration-related	—			(29)			—			29			—			24			0.1		0.07
Amortization of purchased intangible assets	—			—			—			114			—			93			0.4		0.25
Restructuring-related and other charges	—			(29)			—			29			—			26			(0.1)		0.06
Medical device regulations	—			—			(13)			14			—			11			0.1		0.03
Recall-related matters	—			—			—			2			—			2			(0.2)		0.01
Regulatory and legal matters	—			—			—			—			—			—			—		—
Tax matters	—			—			—			—			—			35			(4.6)		0.09
Adjusted	$	2,461		$	1,186		$	229		$	1,047		$	(79)		$	812		16.1	%	$	2.14
Adjusted percent net sales	65.9		%	31.7		%	6.1		%	28.0		%	(2.1)		%	21.7		%